?Product Name?: 3,6-Dichloro-4-isopropylpyridazine (Resmetirom Intermediate)
?CAS No.?: 107228-51-3

?? ?Product Overview?
A critical intermediate in the synthesis of ?Resmetirom? (MGL-3196), a thyroid hormone receptor-β agonist under clinical development for non-alcoholic steatohepatitis (NASH) and metabolic disorders. This compound enables efficient large-scale production of Resmetirom APIs, ensuring high reactivity and compatibility with downstream pharmaceutical processes. Widely used in R&D and commercial manufacturing of thyroid dysfunction therapeutics.

?? ?Key Advantages?
? ?High Reactivity?: ≥98% purity (HPLC/GC-certified), ideal for API synthesis.
? ?Flexible Packaging?: Available in 1kg, 5kg, 25kg bulk quantities; customizable formats.
?? ?Traceable Synthesis?: Batch-specific COA with validated synthesis pathways.

?? ?Applications?

1. ?Pharmaceutical Production?: Core intermediate for Resmetirom (CAS 920509-32-6), targeting NASH and thyroid-related diseases.

2. ?Advanced R&D?: Supports development of novel thyroid receptor agonists and metabolic disorder treatments.

?? ?Quality Certification?

• ?Testing Standards?: HPLC, GC, NMR, and mass spectrometry.

• ?Compliance?: Meets ICH Q7 and ISO 9001 guidelines for pharmaceutical intermediates.

?? ?Market Trends?
Resmetirom’s potential as a first-in-class NASH therapy drives demand for its intermediates. With Resmetirom’s Phase III trials progressing and anticipated FDA approvals (2026-2027), global API production is forecasted to grow at ?10% CAGR? (2025-2030). Suppliers offering scalable, GMP-compliant intermediates will dominate partnerships with leading pharma firms.